Skip to main content

Table 4 Factors influencing development of SI in patients with RA treated with TCZ or TNFIs a

From: Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry

Variable All patients MTX users
HR (95% CI) c P value c HR (95% CI) d P value d
Age by decade 1.34 (0.95 to 1.89) 0.093 1.31 (0.86 to 2.00) 0.210
Female 3.27 (0.77 to 13.98) 0.110 2.20 (0.49 to 9.93) 0.305
Comorbidityb 2.20 (0.95 to 5.11) 0.067 2.49 (0.87 to 7.10) 0.088
PSL ≥5 (mg/day) 2.26 (1.02 to 5.01) 0.046 2.04 (0.77 to 5.44) 0.154
Tocilizumab 2.23 (0.93 to 5.37) 0.074 1.93 (0.72 to 5.17) 0.190
  1. aCox regression hazard models were performed using the independent variables included in the Table; bcomorbidity included pulmonary diseases, diabetes mellitus, liver diseases, and kidney diseases; cCox regression analysis was applied in all patients; dCox regression analysis was applied in patients who were treated with MTX at baseline. CI: confidence interval; HR: hazard ratio; MTX: methotrexate; PSL: prednisolone; RA: rheumatoid arthritis; SI: serious infection; TCZ: tocilizumab; TNFIs: tumor necrosis factor inhibitors.